Pneumonia and other serious adverse events · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lung function · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute respiratory infections study duration: 12 months · patients with chronic obstructive pulmonary disease
It is very uncertain whether PPI plus usual care changes acute respiratory infections study duration: 12 months compared with usual care alone or chronic obstructive pulmonary disease (very low certainty).
1 finding from 1 review
Disease‐specific adverse events · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma exacerbations requiring hospitalisation or a course of steroids · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Change in morning PEF (L/min) at endpoint · people with asthma
It is very uncertain whether atorvastatin changes lung function: change in morning PEF compared with placebo (very low certainty).
1 finding from 1 review
Change from baseline in pre‐bronchodilator FEV1 · people with asthma
It is very uncertain whether atorvastatin changes lung function: change in FEV1 (pre) compared with placebo (very low certainty).
1 finding from 1 review
Lung function: change in FEV1 (post) · people with asthma
It is very uncertain whether atorvastatin changes lung function: change in FEV1 (post) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events or adverse events · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Asthma control · people with asthma
It is very uncertain whether atorvastatin changes asthma control: change in ACQ compared with placebo (very low certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Exacerbations · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in number of participants experiencing an exacerbation within 6 months compared with placebo (low certainty).
2 findings from 1 review
Odds ratio 0.43 [0.06, 2.97]
1 study · 18 participants
Low
Odds ratio 9 [0.75, 108.31]
1 study · 18 participants
Low
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review